A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
A double-blind, randomized, placebo-controlled trial of celecoxib as an add-on therapy to
risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive
first-episode patients with schizophrenia. The study addresses an immune dysfunction
hypothesis of schizophrenia.